CBD for migraines and headaches: is it worth trying and how to use it

Migraine is one of the most disabling neurological diseases — affecting about 15% of the population, it is the third most common disease in the world and the ninth leading cause of disability according to WHO. Classic migraine treatments (triptans, prevention with β-blockers or topiramate) do not work for everyone, and many people seek alternative or complementary methods. CBD attracts attention — both because the endocannabinoid system plays a role in pain regulation and because studies on cannabinoids and migraines yield preliminary promising results. However, the data are in the early stages and require cautious interpretation.

KEY INFORMATION
• Migraine affects about 15% of the population; 40% of patients using cannabinoids reported a reduction in attacks of over 50% (Aviram and Samuelly-Leichtag, Frontiers in Pharmacology, 2017).
• CBD may act on migraines through TRPV1 receptors (pain sensitivity), inhibition of neurogenic inflammation, and modulation of the serotonin system.
• The endocannabinoid deficiency (CED) hypothesis may explain the biological link between migraines and CBD (Russo, Neuroendocrinology Letters, 2008).
• There is a lack of large randomized clinical trials with CBD alone for migraines — data concern cannabinoids (CBD+THC) or CBD in small trials.
• Prophylactic dose of CBD: 15–25 mg/day for 4–8 weeks; during an attack: 25–75 mg as soon as possible.

Why is the endocannabinoid system important for migraines?

Before we delve into the research data, it is worth understanding the biological link between migraines and the endocannabinoid system. This connection is not coincidental — the endocannabinoid system (ECS) is actively involved in regulating processes underlying migraines: pain sensitivity, neurogenic inflammation, vascular tension, and neurotransmitter modulation.

Dr Ethan Russo (Neuroendocrinology Letters, 2008) proposed the "clinical endocannabinoid deficiency" (CED) hypothesis, which suggests that migraines, fibromyalgia, and irritable bowel syndrome may be related to insufficient functioning of the endocannabinoid system — too little endogenous cannabinoids (anandamide and 2-AG) or reduced reactivity of CB1 and CB2 receptors.

The CED hypothesis has several lines of evidence. First: the level of anandamide in the cerebrospinal fluid of migraine patients is statistically lower than in healthy individuals — as shown by a study Sarchielli et al. (Neuropsychopharmacology, 2007). Second: activation of CB1 receptors by cannabinoids inhibits the release of CGRP (calcitonin gene-related peptide) — a key neuropeptide in the pathogenesis of migraine pain, which is the target of new migraine medications (gepants, monoclonal anti-CGRP antibodies).

What do studies say about CBD and migraines?

There is little clinical data on isolated CBD for migraines — most studies have focused on cannabinoids as a group (CBD+THC) or medical marijuana in general. This limits the ability to draw conclusions solely about CBD, but indicates a direction.

The most frequently cited study is the work Aviram i Samuelly-Leichtag (Frontiers in Pharmacology, 2017) — an observational study of 48 migraine patients using medical cannabinoids (a mix of CBD and THC) in Israel. Results: 40% of participants reported a reduction in attack frequency of over 50%, and 85% rated cannabinoids as "beneficial." The intensity of pain during an attack decreased by an average of 3.6 points on a 10-point scale. These are promising data — but with a mixture of CBD+THC and without a control group.

Study Rhyne et al. (Pharmacotherapy, 2016) conducted a retrospective analysis of medical records of patients using medical marijuana for migraines. Results: the monthly frequency of migraine attacks decreased from 10.4 to 4.6 — a reduction of 55.7%. Some patients used CBD-dominant strains, while others used THC-dominant ones. These are retrospective data, without randomization, but clinically significant reduction.

A key caveat: there has not yet been a large, randomized, double-blind clinical trial evaluating CBD alone (without THC) for migraines. This is a common issue throughout the CBD literature — the difficulty in obtaining funding for studies with a substance that has been illegal for decades. All results should be treated as preliminary, promising hypotheses requiring confirmation.

How CBD may work for migraines – mechanisms

The mechanisms through which CBD may potentially alleviate migraines or reduce their frequency involve several molecular pathways.

Modulation of TRPV1 receptors: TRPV1 receptors (vanilloid, channel) regulate the sensitivity of nociceptors — sensory neurons that transmit pain signals. Hyperactivity of these neurons is one of the mechanisms in the pathogenesis of migraines (the phenomenon of "central sensitization"). CBD, as a TRPV1 modulator, may reduce this hyperactivity, raising the pain threshold.

Hamowanie zapalenia neurogennego: In migraines, substance P and CGRP are released by the trigeminal nervous system — neuropeptides that cause neurogenic inflammation around the meningeal vessels. CBD can modulate the release of these neuropeptides through CB1 and TRPV1 receptors, reducing the intensity of neurogenic inflammation.

Serotonina i 5-HT1B: Serotonin receptors play a key role in migraines — triptans (sumatriptan, rizatriptan) work through agonism of 5-HT1B/1D, causing vasoconstriction and blocking neurogenic inflammation. CBD, as a 5-HT1A agonist, may have similar, albeit weaker, effects through modulation of serotonergic tone.

Wzrost poziomu anandamidu: CBD inhibits the FAAH enzyme, which degrades anandamide. A higher level of anandamide (the endogenous cannabinoid analogue of THC) may correct a potential endocannabinoid deficiency proposed by the CED hypothesis. Sarchielli et al. (Neuropsychopharmacology, 2007) They demonstrated that patients with migraines have lower levels of anandamide in cerebrospinal fluid — making FAAH inhibitors (including CBD) interesting therapeutic candidates.

CBD prophylactically vs during an attack – two different approaches

When using CBD in the context of migraines, we have two distinct strategies: prophylactic (daily use between attacks to reduce their frequency) and acute (during an attack to alleviate its intensity and duration). Both have logical justification but differ in dosing and expectations.

Profilaktycznie: Daily use of CBD aims to build endocannabinoid tone and reduce central sensitivity — processes that require time. Studies on migraines have used cannabinoids prophylactically for at least 4–8 weeks before assessing changes in attack frequency. Prophylactic dose: 15–25 mg of CBD daily. Regularity is key — similar to β-blockers or topiramate used in migraine prevention. Evaluate results after a minimum of 8 weeks.

Podczas napadu: The use of CBD during a migraine attack aims to alleviate pain, nausea (through CB1 receptors), and accompanying sensitivity to light and sound. Acute dose: 25–75 mg of CBD as soon as possible after the first signs of an attack. Sublingual administration (bioavailability 13–19%) provides a faster effect than swallowing a capsule (bioavailability 4–8%). Important note: CBD is not a substitute for triptans in severe migraine attacks — if you have prescribed triptans and they work, do not discontinue them in favor of CBD without consulting a neurologist.

Praktyczny plan stosowania CBD przy migrenie

If you decide to test CBD for migraines, the following protocol provides a structure for assessing effectiveness:

Tygodnie 1–2: Faza startowa. CBD 15 mg daily in the evening (3 drops of 5% oil or 3 drops of 10% oil). Goal: check tolerance, no adverse effects. Concurrently: keep a migraine diary — date, duration, intensity (1–10), possible triggers. This diary is crucial for assessing change.

Tygodnie 3–6: Faza terapeutyczna. Increase to 25 mg of CBD daily. Take regularly at a fixed time — morning or evening. During a migraine attack: take an additional dose of 25–50 mg sublingually as soon as possible after the first signs. Continue the diary and compare the frequency and intensity of attacks with previous months.

Week 8+: Evaluation. Compare the average monthly frequency of attacks and their intensity with the baseline before CBD. A reduction of 30%+ is clinically significant and indicates a positive response. No change at 25 mg/day — consider increasing to 40–50 mg or consult a neurologist specializing in migraines.

Our observations: Users with migraines who use CBD most often describe not so much complete relief from attacks, but "reduction in their intensity" and "shortening of duration" — which translates to less consumption of triptans and shorter disability. This is a realistic expectation to have before starting. CBD for migraines is support, not a first-line medication.

CBD and nausea and vomiting during a migraine attack

One of the most debilitating aspects of a migraine attack is the accompanying nausea and vomiting. They can prevent the intake of pills (including oral triptans), complicating treatment. CBD and the endocannabinoid system have a well-documented effect on nausea.

CB1 receptors are densely represented in the solitary nucleus (nucleus tractus solitarii) and the chemoreceptor trigger zone of the brainstem — areas that regulate vomiting. Activation of CB1 by cannabinoids slows proemetic signals. Parker et al. (Frontiers in Pharmacology, 2011) They demonstrated that cannabinoids, including CBD, effectively reduced nausea in animal models and in several pilot studies in oncology patients undergoing chemotherapy.

In a migraine attack with severe nausea, sublingual administration of CBD (rather than oral) has an additional practical advantage — it does not require swallowing during nausea. A sublingual dose of 25–50 mg of CBD may alleviate both headache and accompanying nausea. In cases of severe vomiting that prevent any oral administration — traditional antiemetic medications (domperidone, metoclopramide) or sumatriptan in injection or suppository form are a medical priority.

Hormonal migraine in women – can CBD help?

About 70% of women with migraines experience so-called menstrual migraines or increased attack frequency in connection with the hormonal cycle. A drop in estrogen before menstruation triggers a migraine attack through a mechanism that increases the sensitivity of the trigeminal nervous system. Does CBD have a special role here?

Estrogen modulates the density of cannabinoid CB1 receptors — higher estrogen = more CB1 and higher reactivity to cannabinoids. Therefore, the effectiveness of CBD may naturally vary throughout the menstrual cycle: in the follicular phase (higher estrogen), CBD may work more effectively than in the luteal phase or during menstruation (lower estrogen). This is not clinically proven — it is a mechanistic observation suggesting variability in response.

Practical implication: for menstrual migraines, CBD may require a higher dose in the days around menstruation (2–3 days before and during menstruation) than on other days of the cycle. Several women using CBD prophylactically for menstrual migraines describe this variability and adjust the dose — this is consistent with the pharmacological mechanism. There are no randomized clinical trials confirming this observation.

CBD and tension-type headaches – a separate category

Migraine and tension-type headaches are distinct clinical entities, although they are often confused. Tension-type headaches (TTH) are the most common type of headache — affecting about 40% of the population and have a different mechanism than migraines: primarily increased tension in the neck and shoulder muscles, without a pulsating character and without sensitivity to light. CBD may be helpful for TTH through muscle-relaxing effects (by modulating CB2 receptors in muscles) and anti-inflammatory effects, but the mechanism is different than for migraines.

For tension-type headaches, CBD works best in combination with strategies that reduce muscle tension: stretching, neck and shoulder exercises, stress reduction. CBD alone without addressing the triggering factor (tension, posture, stress) will yield limited effects. A full description of dosing for musculoskeletal pain can be found in the article. CBD for back and joint pain..

Safety and interactions with migraine medications

The safety profile of CBD is good — as repeatedly indicated by the WHO report from 2018. However, in the case of migraines, potential interactions with neurological medications are significant.

CBD is metabolized by the enzymes CYP3A4 and CYP2C19, which process, among others, some migraine prophylactic medications: topiramate (Topamax), sodium valproate (Depakine), and amitriptyline. Inhibition of these enzymes by CBD may increase the concentration of these drugs in the blood — potentially enhancing both their effectiveness and side effects. Badanie opublikowane w Epilepsia (2020) It has been shown that CBD increases the concentration of clobazam (similar metabolic pathway) by about 60%.

Triptans (sumatriptan, eletriptan, almotriptan) are primarily metabolized by monoamine oxidase A (MAO-A) and to a lesser extent by CYP3A4 — the risk of interaction with CBD is lower than with prophylactic medications, but not zero. When using triptans in combination with CBD: monitor whether the effect of triptans is stronger than usual or if new side effects appear. If so — consult a neurologist.

Profilaktyczne dawkowanie CBD znajdziesz w artykule CBD dosing – how many drops to take.

Frequently Asked Questions

Does CBD help with migraines?

Preliminary studies suggest that cannabinoids may alleviate migraines. Aviram i Samuelly-Leichtag (Frontiers in Pharmacology, 2017) They demonstrated a reduction in attacks of over 50% in 40% of patients using cannabinoids. There are no large RCTs with CBD alone for migraines — the data is preliminary but consistent with mechanistic justification.

How much CBD to take for migraines?

Prophylactically: 15–25 mg/day for at least 8 weeks. During an attack: 25–75 mg of CBD sublingually as soon as the first signs appear. Increase slowly — by 5–10 mg each week — if the prophylactic dose is insufficient.

Can CBD prevent migraines?

The CED (Clinical Endocannabinoid Deficiency) hypothesis posits that a deficiency of anandamide may underlie migraines. Sarchielli et al. (Neuropsychopharmacology, 2007) They showed lower levels of anandamide in patients with migraines. CBD, through FAAH inhibition, raises anandamide levels — which may prophylactically reduce the frequency of attacks. Preliminary observational data supports this hypothesis.

CBD for a migraine attack – when to take it?

As soon as possible after the first signs of an attack (aura or onset of pain). Sublingual administration provides faster bioavailability. Dose during an attack: 25–75 mg of CBD. CBD is not a substitute for triptans in severe attacks — consider it as a supplement or alternative for mild to moderate attacks.

Does CBD interact with migraine medications?

Potentially yes — CBD may alter the concentration of migraine prophylactic medications (topiramate, valproate) metabolized by CYP3A4 and CYP2C19. When using these prescription medications, always consult a neurologist before incorporating CBD.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a physician, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04